Syndax制药公司的财务情况比预期的要好,但主要投资者却出售股票。 Syndax Pharmaceuticals showed better-than-expected financials, yet major investors sold off shares.

Syndax制药公司报告第四季度的损失额低于预期,收入增加。 Syndax Pharmaceuticals reported a smaller-than-expected loss and higher revenue in the fourth quarter. 尽管如此,一些主要投资者,包括Brevan Howard资本管理公司和Schonfeld战略顾问公司,减少了在该公司的股票持有量。 Despite this, several major investors, including Brevan Howard Capital Management and Schonfeld Strategic Advisors, reduced their stock holdings in the company. Stifel金融公司增加其持有量。 Stifel Financial Corp increased its holdings. 该公司侧重于发展癌症疗法。 The company focuses on developing cancer therapies.